UPCC 06220: A Phase II Randomized Controlled Trial | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase 2

1 Location

Brief description of study

The purpose of this research study is to determine whether treatment with HuMax-IL8 in combination with nivolumab has additional benefit to nivolumab treatment alone for treatment of hepatocellular carcinoma (HCC). Eligible subjects will have advanced HCC.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 14 Oct 2020. Study ID: 843688

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

View email

Phone

View phone

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Please provide your preferred way of contact

Race

Select race of your choice

Ethnicity

Select ethinicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center

UPCC 06220: A Phase II Randomized Controlled Trial of Nivolumab in Combination with BMS-986253 or Cabiralizumab in Advanced Hepatocellular Carcinoma (HCC) Patients

Brief description of study

Eligibility of study

Find a site

Interested in the study